Abstracts tagged "Infection"

Abstract Number: 1457 • 2017 ACR/ARHP Annual Meeting
Perioperative Management of Methotrexate and Tumor Necrosis Factor Inhibitor Combination Therapy in Rheumatoid Arthritis Patients
Hsin-Hsuan Juo^1,2 and Bernard Ng^1,3, ¹rheumatology, University of Washington, seattle, WA, ²rheumatology, VA Puget Sound Health Care System, seattle, WA, ³Rheumatology, VA Puget Sound Health Care System, seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher frequency of requiring surgical procedures and worse surgical outcome. However, literature regarding post-surgical infectious outcome associated with…
Abstract Number: 1587 • 2017 ACR/ARHP Annual Meeting
Mycobacterial Infection in Systemic Lupus Erythematosus: Clinical Significance and Associated Factors. Data from the Registry of Patients with SLE of the Spanish Society of Rheumatology (RELESSER)
Ana Lois-Iglesias¹, Víctor del Campo-Pérez², Iñigo Rúa-Figueroa³, Coral Mouriño-Rodriguez⁴, Francisco Javier López Longo⁵, María Galindo⁶, Jaime Calvo-Alen⁷, Jesús Ibañez Ruán⁸, Alejandro Olivé⁹, Rafael-Benito Melero González⁴, Antonio Fernandez-Nebro¹⁰, José Antonio Bernal¹¹, Celia Erausquin¹², Eva Tomero¹³, Maria Loreto Horcada¹⁴, Esther Uriarte¹⁵, Mercedes Freire¹⁶, Carlos Alberto Montilla-Morales¹⁷, Ana Sánchez Atrio¹⁸, Alina Boteanu¹⁹, Elvira Diez Alvarez²⁰, Javier Narváez²¹, Víctor Martínez Taboada²², Lucía Silva Fernández²³, Esther Ruiz Lucea²⁴, Jose Luis Andreu²⁵, José Hernández Beiraín²⁶, Marian Gantes²⁷, Blanca Hernández-Cruz²⁸, Jose Javier Perez Venegas²⁹, Ángela Pecondón Español³⁰, Nuria Lozano-Rivas³¹, Monica Ibanez Barcelo³², Gema Bonilla³³, Vicente Torrente³⁴, Ivan Castellví³⁵, Juan José Alegre³⁶, Mireia Moreno³⁷, José Luis Marenco de la Fuente³⁸, Cesar Magro-Checa³⁹, Tomás Vázquez Rodríguez⁴⁰, Victor Quevedo⁴¹, Patricia Richi⁴², Maria Teresa Oton Sanchez⁴³ and JM Pego-Reigosa⁴⁴, ¹Rheumatology, University Hospital A Coruña, A Coruña, Spain, ²Preventive Medicine and Epidemiology, EOXI Vigo, Vigo, Spain, ³Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁴Rheumatology, EOXI Vigo, Vigo, Spain, ⁵Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ⁶Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ⁸POVISA, Rheumatology, Vigo, Spain, ⁹Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁰Rheumatology, Regional Universitary Hospital of Málaga, Malaga, Spain, ¹¹Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, ¹²Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain, ¹³Hospital La Princesa. Madrid., Madrid, Spain, ¹⁴Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁵Reumatología, Hospital de Donosti, Donosti, Spain, ¹⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁷Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹⁸University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain, ¹⁹University Hospital Ramón y Cajal, Madrid, Spain, ²⁰Complejo Asistencial Universitario de León. León. Spain, León, Spain, ²¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²²Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ²³Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²⁴Hospital de Basurto, Bilbao, Spain, ²⁵Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²⁷Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ²⁸Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ²⁹Rheumatology, Hospital de Jerez de la Frontera, Jerez de la Frontera, Spain, ³⁰Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ³¹Rheumatology, Hospital Virgen de la Arrixaca, murcia, Spain, ³²H. Son Llatzer, Palma de Mallorca, Spain, ³³Hospital Universitario La Paz, Madrid, Spain, ³⁴Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain, ³⁵Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ³⁶Sección de Reumatología Hospital Universitario Dr Peset Valencia, Valencia, Spain, ³⁷Rheumatology, Hospital Universitari Parc Taulí, Sabadell, Spain, ³⁸Rheumatology, Hospital de Valme, Seville, Spain, ³⁹Department of Rheumatology, Leiden University Medical Center, Leiden, Spain, ⁴⁰Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ⁴¹Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴²Hospital Infanta Sofía, Madrid, Spain, ⁴³Rheumatology Department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ⁴⁴Rheumatology Section, Hospital de Meixoeiro, Pontevedra, Spain, Vigo, Spain
Background/Purpose: The aim of this work is to study the prevalence of mycobacterial infection (M.I.), the associated factors and their clinical significance in patients included…
Abstract Number: 1967 • 2017 ACR/ARHP Annual Meeting
Strongyloides Screening in Immunocompromised Immigrant Rheumatology Patients
Sahitya Mallipeddi¹, Christina Coyle² and Beverly Johnson¹, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Infectious Diseases, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Strongyloides Stercoralis is a helminthic infection that is usually chronic and asymptomatic and may persist undiagnosed for decades. Patients from strongyloides endemic areas (tropics…
Abstract Number: 1972 • 2017 ACR/ARHP Annual Meeting
Causes of Death in 350 Patients with Systemic Autoimmune Rheumatic Diseases
Juan Gabriel Ovalles-Bonilla^1,2, Olaia Fernández-Berrizbeitia³, Julia Martínez-Barrio¹, Larissa Valor¹, Diana Hernández¹, Iustina Janta¹, Belen Serrano¹, Claudia Saez¹, Roberto Gonzalez¹, María Correyero¹, Leticia García¹, Ana López-Cerón¹, Alicia Silva¹, Juan Carlos Nieto¹, Carlos González^1,4, Indalecio Monteagudo¹ and Francisco Javier López Longo^1,4, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital Universitario Basurto, Bilbao, Spain, ⁴Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The major SARD have an increased mortality compared to the general population. It is well known that the main causes of death in Systemic…
Abstract Number: 2082 • 2017 ACR/ARHP Annual Meeting
Clinical Presentation, Management, and Prognosis of Pseudogout in Prosthetic Joint Implant Patients: A Retrospective Study
Merit P. George¹, Floranne C. Ernste², Aaron J. Tande³, Douglas R. Osmon³, Tad M. Mabry⁴ and Elie F. Berbari³, ¹Mayo Clinic School of Medicine, Rochester, MN, ²Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ³Division of Infectious Diseases, Mayo Clinic Rochester, Rochester, MN, ⁴Division of Orthopedic Surgery, Mayo Clinic Rochester, Rochester, MN
Background/Purpose: The prevalence of total knee arthroplasty (TKA) and total hip arthroplasty (THA) has risen considerably in the U.S. There has been a relative lack…
Abstract Number: 271 • 2017 ACR/ARHP Annual Meeting
The Trend of Incidence Rate, Frequency and HLA Phenotype of Reactive Arthritis and Uveitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20-Year, Two-Center Retrospective Study
Yoshinori Taniguchi¹, Satoshi Inotani², Hirofumi Nishikawa², Kosuke Inoue³, Taro Horino², Takashi Karashima⁴, Yasuhiko Yoshinaga⁵ and Yoshio Terada³, ¹Endocrinology, Metabolism,Nephrology and Rheumatology, Kochi University, Kochi, Japan, ²Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, ³Kochi University, Nankoku, Japan, ⁴Urology, Kochi University, Nankoku, Japan, ⁵Kurashiki Medical Center, Kurashiki, Japan
Background/Purpose: Intravesical instillation of Bacillus Calmette-Guerin (iBCG) is used as an effective immunotherapy of bladder cancer. However it may have, as adverse event, a reactive…
Abstract Number: 2140 • 2017 ACR/ARHP Annual Meeting
Infections and Medications Associated with Onset of Myositis in Myovision, a National Myositis Patient Registry
Lisa G Rider¹, Payam Noroozi Farhadi¹, Nastaran Bayat¹, Jesse Wilkerson², Abdullah Faiq¹, John McGrath², Hermine I. Brunner³, Bob Goldberg⁴ and Frederick W Miller¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Social and Scientific Systems, Inc., Durham, NC, ³Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴The Myositis Association, Alexandria, VA
Background/Purpose: Myositis is a rare systemic autoimmune disease with suspected environmental and genetic risk factors, but little is known about specific infections and medications that…
Abstract Number: 1317 • 2016 ACR/ARHP Annual Meeting
Do Patients with MRSA-Positive Septic Arthritis Differ Clinically from Non-MRSA-Positive Counterparts?
Mary Louise Fowler¹, Kevin Byrne¹, Sarah B. Lieber², Andy Moore³, Robert Shmerling⁴ and Ziv Paz², ¹Boston University School of Medicine, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Division of Rheumatology, Cambridge Health Alliance, Harvard Medical School, Boston, MA, ⁴Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA
Do patients with MRSA-positive septic arthritis differ clinically from non-MRSA-positive counterparts? Mary Louise Fowler3, Kevin Byrne3, Sarah B. Lieber1, Andrew Moore2, Robert H. Shmerling1, Ziv…
Abstract Number: 1351 • 2016 ACR/ARHP Annual Meeting
Mortality and Prognostic Factors of Pneumocystis Pneumonia in Patients with Connective Tissue Diseases
Mitsuhiro Akiyama¹, Yuko Kaneko² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine,, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is one of the severe opportunistic infections in immunocompromised patients. PCP is still a leading cause of death in patients with…
Abstract Number: 1502 • 2016 ACR/ARHP Annual Meeting
Vaccination Program to Prevent Hospital Admissions Due to Serious Respiratory Infections in Rheumatoid Arthritis Patients. Prosprective Study of 294 Patients
Lucia C. Domínguez-Casas¹, Paz Rodríguez-Cundín², Vanesa Calvo-Río¹, Ricardo Blanco¹, Nuria Vegas-Revenga³, Carlos Fernández Díaz¹, Virginia Portilla³, FM Antolin², MH Rebollo-Rodrigo², Alfonso Corrales¹, Natalia Palmou-Fontana¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of infections, especially serious respiratory infections. Immunization is a recommended to reduce these complications.…
Abstract Number: 1684 • 2016 ACR/ARHP Annual Meeting
Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Christopher T. Ritchlin¹, Alan Menter², Philip J Mease³, Sunil Kalia⁴, Francisco Kerdel⁵, Shelly Kafka⁶, James Morgan⁶, Wayne Langholff⁷, Steve Fakharzadeh⁶, Kavitha Goyal⁶ and Alice Gottlieb⁸, ¹Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Baylor Research Institute, Dallas, TX, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵University of Miami, Miami, FL, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Tufts University School of Medicine (affiliation at the time of the study), Boston, MA
Background/Purpose: To describe the rates of serious infections (SI) in psoriasis (PsO) pts with psoriatic arthritis (PsA) from PSOLAR, & assess risk with biologic therapy.…
Abstract Number: 1925 • 2016 ACR/ARHP Annual Meeting
Interest of Procalcitonin for the Follow-up of ANCA-Associated Vasculitis: Data from a Cohort of 99 Patients
Anne Lemaire¹, Roderau Outh¹, Alexandre Mania¹, Geoffroy Marceau², Pauline Berland³, Marc Andre⁴ and Olivier Aumaître⁵, ¹Internal Medicine CHU G Montpied, Internal Medicine, CLERMONT-FERRAND, France, ²Biology, Medical Biochemistry, CLERMONT-FERRAND, France, ³Epidemiology, Epidemiology, CLERMONT-FERRAND, France, ⁴Internal Medicine CHU G Montpied, Internal Medicine, Clermont Ferrand, France, ⁵Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France
Background/Purpose: The prognosis of the ANCA associated vasculitis (AAV) has improved with the new immunosuppressive treatments but infectious complications remain frequent. Procalcitonin (PCT) is…
Abstract Number: 403 • 2016 ACR/ARHP Annual Meeting
High Rate of Serious Infection in Juvenile Idiopathic Arthritis Under Biologic Therapy in a Real Life Setting
Juliana Brunelli¹, Ana Renata Schmidt¹, Adriana M E Sallum², Cláudia Goldenstein-Schainberg³, Eloisa Bonfa⁴, Clovis A Silva⁵ and Nadia E Aikawa⁶, ¹Pediatric Rheumatology, University of São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ³Rheumatology Division, University of São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁶Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Most data about infections associated to biologic therapy in juvenile idiopathic arthritis (JIA) derive from registries designed to identify general adverse events that have…
Abstract Number: 2049 • 2016 ACR/ARHP Annual Meeting
Serious Infections in RA Offspring Exposed to Tumor Necrosis Factor Inhibitors
Evelyne Vinet¹, Cristiano S. Moura², Jeffrey R. Curtis³, Christian A. Pineau⁴, Michal Abrahamowicz² and Sasha Bernatsky⁵, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Center for Education and Research on Therapeutics, University of Alabama at Birmingham, Birmingham, AL, ⁴McGill University Health Centre, Montreal, QC, Canada, ⁵Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are increasingly used during RA pregnancy. Most of these are actively transported across the placenta, reaching higher fetal than maternal…
Abstract Number: 523 • 2016 ACR/ARHP Annual Meeting
Mortality Profile of Patients with Rheumatoid Arthritis in France and Its Change in 10 Years
Jerome Avouac¹, Fazia Amrouche², Christophe Meune³, Grégoire Rey⁴, Andre Kahan⁵ and Yannick Allanore⁶, ¹Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Paris Descartes University, Cochin Hospital, Paris, France, ³Cardiology department, Université Paris XIII, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Bobigny, France, ⁴Inserm-CépiDc, Hospital Bicêtre, Le Kremlin-Bicêtre, France, ⁵Service de Rhumatologie A, Hopital Cochin, Paris Cedex 14, France, ⁶Rheumatology, Paris Descartes University, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with an excess of mortality. This risk depends on the disease activity, severity and associated comorbidities. Our objective was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].